<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="134434">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01840579</url>
  </required_header>
  <id_info>
    <org_study_id>3475-011</org_study_id>
    <nct_id>NCT01840579</nct_id>
  </id_info>
  <brief_title>Study of Pembrolizumab (MK-3475) Monotherapy in Participants With Advanced Solid Tumors and Pembrolizumab Combination Therapy in Participants With Advanced Non-small Cell Lung Cancer (MK-3475-011/KEYNOTE-011)</brief_title>
  <official_title>A Phase I Study of MK-3475 Alone in Subjects With Advanced Solid Tumors and in Combination With Cisplatin/Pemetrexed or Carboplatin/Paclitaxel in Subjects With Advanced Non-Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <authority>Japan: Pharmaceuticals and Medical Devices Agency</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study using pembrolizumab (MK-3475) will be done in 2 parts.  In Part A successive
      participant cohorts with advanced solid tumors will receive pembrolizumab to find the best
      dose level for Part B.  If no tolerable dose is found, Part B will not begin. In Part B
      participants with advanced non-small cell lung cancer (NSCLC)  will receive pembrolizumab in
      combination with either cisplatin/pemetrexed or carboplatin/paclitaxel by non-random
      assignment to assess the safety and tolerability of the combination therapy.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Anticipated">April 2015</completion_date>
  <primary_completion_date type="Anticipated">April 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Number of participants experiencing dose-limiting toxicities (DLTs)</measure>
    <time_frame>Cycle 1 (first dose up to 4 weeks)</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Solid Tumor</condition>
  <condition>Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Pembrolizumab Low Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive pembrolizumab intravenously (IV) on Day 1 of each cycle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pembrolizumab Higher Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive pembrolizumab intravenously (IV) on Day 1 of each cycle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pembrolizumab Higher dose/cisplatin/pemetrexed</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive pembrolizumab intravenously (IV) on Day 1 of each cycle, and cisplatin and pemetrexed per institutional standard.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pembrolizumab Higher Dose/carboplatin/paclitaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive pembrolizumab intravenously (IV) on Day 1 of each cycle, and carboplatin and paclitaxel per institutional standard.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <arm_group_label>Pembrolizumab Low Dose</arm_group_label>
    <arm_group_label>Pembrolizumab Higher Dose</arm_group_label>
    <arm_group_label>Pembrolizumab Higher dose/cisplatin/pemetrexed</arm_group_label>
    <arm_group_label>Pembrolizumab Higher Dose/carboplatin/paclitaxel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <arm_group_label>Pembrolizumab Higher dose/cisplatin/pemetrexed</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pemetrexed</intervention_name>
    <arm_group_label>Pembrolizumab Higher dose/cisplatin/pemetrexed</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <arm_group_label>Pembrolizumab Higher Dose/carboplatin/paclitaxel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <arm_group_label>Pembrolizumab Higher Dose/carboplatin/paclitaxel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  In Part A: histological or cytological diagnosis of solid tumor, progressive
             metastatic disease, or progressive locally advanced disease not amenable to local
             therapy

          -  In Part B: histologically- or cytologically-confirmed diagnosis of NSCLC (Stage
             IIIB/IV)

          -  Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1

          -  Adequate organ function

        Exclusion criteria:

          -  Cancer therapy within 4 weeks prior to the first dose of study therapy, or not
             recovered from the adverse events of agents administered more than 4 weeks prior to
             the first dose of study therapy.

          -  Currently participating or has participated in a study with an investigational agent
             or using an investigational device within 30 days of first dose of study therapy

          -  Expected to require any other form of antineoplastic therapy while on study

          -  On chronic systemic steroid therapy within two weeks prior to the first dose of trial
             treatment or on any other form of immunosuppressive medication
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Toll Free Number</last_name>
    <phone>1-888-577-8839</phone>
  </overall_contact>
  <location>
    <facility>
      <name>MSD K.K.</name>
      <address>
        <city>Chiyoda-Ku, Tokyo</city>
        <zip>102-8667</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Japan Call Center</last_name>
      <phone>81-3-6272-1957</phone>
    </contact>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>June 2014</verification_date>
  <lastchanged_date>June 2, 2014</lastchanged_date>
  <firstreceived_date>April 23, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pemetrexed</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
